JP2023552765A5 - - Google Patents
Info
- Publication number
- JP2023552765A5 JP2023552765A5 JP2023533881A JP2023533881A JP2023552765A5 JP 2023552765 A5 JP2023552765 A5 JP 2023552765A5 JP 2023533881 A JP2023533881 A JP 2023533881A JP 2023533881 A JP2023533881 A JP 2023533881A JP 2023552765 A5 JP2023552765 A5 JP 2023552765A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence seq
- amino acid
- acid sequence
- light chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011402162.XA CN114573702A (zh) | 2020-12-02 | 2020-12-02 | 一种新型肿瘤衔接器治疗药物的开发和应用 |
| CN202011402162.X | 2020-12-02 | ||
| PCT/CN2021/135153 WO2022117050A1 (zh) | 2020-12-02 | 2021-12-02 | 一种新型肿瘤衔接器治疗药物的开发和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552765A JP2023552765A (ja) | 2023-12-19 |
| JP2023552765A5 true JP2023552765A5 (https=) | 2024-04-15 |
| JP7667857B2 JP7667857B2 (ja) | 2025-04-23 |
Family
ID=81769955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533881A Active JP7667857B2 (ja) | 2020-12-02 | 2021-12-02 | 新規な腫瘍エンゲージャ治療剤の開発及び使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240043568A1 (https=) |
| EP (1) | EP4257612A4 (https=) |
| JP (1) | JP7667857B2 (https=) |
| KR (1) | KR20230117183A (https=) |
| CN (2) | CN114573702A (https=) |
| AU (1) | AU2021390123B2 (https=) |
| CA (1) | CA3200813A1 (https=) |
| WO (1) | WO2022117050A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114524878B (zh) * | 2020-11-23 | 2024-08-02 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| CN114573702A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种新型肿瘤衔接器治疗药物的开发和应用 |
| WO2022173035A1 (ja) * | 2021-02-15 | 2022-08-18 | キヤノンメディカルシステムズ株式会社 | 成人スティル病の検査方法及び検査キット |
| WO2025006613A1 (en) * | 2023-06-27 | 2025-01-02 | Hopewell Therapeutics, Inc. | Lipid nanoparticles for cancer immunotherapy |
| WO2025078400A1 (en) * | 2023-10-10 | 2025-04-17 | Astrazeneca Ab | T cell binding compositions and methods |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| JP4658125B2 (ja) | 2005-06-28 | 2011-03-23 | パイオニア株式会社 | 放送受信装置、妨害検出装置および妨害検出方法 |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CN103833852A (zh) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
| WO2015172341A1 (zh) * | 2014-05-14 | 2015-11-19 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
| ES2883240T3 (es) | 2015-08-03 | 2021-12-07 | Cafa Therapeutics Ltd | Anticuerpo contra glipicano-3 y aplicación del mismo |
| CN107556387A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用 |
| CN106591371A (zh) | 2016-11-25 | 2017-04-26 | 哈尔滨百伊生生物科技有限公司 | Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用 |
| MX2019008221A (es) | 2017-01-10 | 2019-12-09 | Univ Yamaguchi | Anticuerpo anti-gpc3. |
| CN108383911A (zh) | 2018-02-06 | 2018-08-10 | 广州市拜沃思生物科技有限公司 | 一种双特异性抗体及其制备方法和应用 |
| CN112010982B (zh) * | 2020-08-31 | 2023-06-27 | 重庆金迈博生物科技有限公司 | 一种抗gpc3/cd3双特异性抗体及其应用 |
| CN114524878B (zh) * | 2020-11-23 | 2024-08-02 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| CN114573702A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种新型肿瘤衔接器治疗药物的开发和应用 |
-
2020
- 2020-12-02 CN CN202011402162.XA patent/CN114573702A/zh active Pending
-
2021
- 2021-12-02 JP JP2023533881A patent/JP7667857B2/ja active Active
- 2021-12-02 US US18/265,114 patent/US20240043568A1/en active Pending
- 2021-12-02 WO PCT/CN2021/135153 patent/WO2022117050A1/zh not_active Ceased
- 2021-12-02 KR KR1020237022098A patent/KR20230117183A/ko active Pending
- 2021-12-02 AU AU2021390123A patent/AU2021390123B2/en active Active
- 2021-12-02 CN CN202180081609.4A patent/CN116601296A/zh active Pending
- 2021-12-02 CA CA3200813A patent/CA3200813A1/en active Pending
- 2021-12-02 EP EP21900076.7A patent/EP4257612A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552765A5 (https=) | ||
| JP2014517823A5 (https=) | ||
| JP2013529904A5 (https=) | ||
| JP2023052214A5 (https=) | ||
| JP2023052839A5 (https=) | ||
| CN104220095B (zh) | 肝癌的治疗和/或预防用药物组合物 | |
| ES2551439T3 (es) | Fragmentos Fab de anticuerpos modificados | |
| JP2013534809A5 (https=) | ||
| JP2023106433A5 (https=) | ||
| CN104203281A (zh) | 胆囊癌的治疗和/或预防用药物组合物 | |
| JP2014507138A5 (https=) | ||
| RS61781B1 (sr) | Antitela koja ciljaju antigen za sazrevanje b-ćelija i postupci upotrebe | |
| HRP20161216T1 (hr) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| JP2020522473A5 (https=) | ||
| AU2021390123B2 (en) | Development of new tumor engager therapeutic drug and use thereof | |
| US20200255536A1 (en) | Target for b-cell disorders | |
| CN102089004B (zh) | 癌的治疗及预防用药物组合物 | |
| CN1381461A (zh) | 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用 | |
| JP2025530888A5 (https=) | ||
| CN117279950A (zh) | 一种靶向il-18bp的抗体及其应用 | |
| RU2007140311A (ru) | Антитела и родственные молекулы, связываюшиеся с белками 161p2f10b | |
| Gilliland et al. | Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells. | |
| CN117177999B (zh) | 一种靶向IL-18Rβ的抗体及其应用 | |
| CN114605542B (zh) | 抗fshr抗体及其抗体-药物偶联物的制备和应用 | |
| JP2022502079A5 (https=) |